ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologicals"

  • Abstract Number: 1123 • ACR Convergence 2023

    Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

    John Botson1, Qianhong Fu2, Kaiding Zhu2, Lissa Padnick-Silver2 and Brian LaMoreaux2, 1Orthopedic Physicians Alaska, Anchorage, AK, 2Horizon Therapeutics, Deerfield, IL

    Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…
  • Abstract Number: 1334 • ACR Convergence 2023

    Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

    Marina Birck1, Luck Lukusa2, Michal Abrahamowicz3, Gilles Boire4, Denis Choquette5, Walter P. Maksymowych6 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2RI-MUHC, Montreal, QC, Canada, 3McGill University, Verdun, QC, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
  • Abstract Number: 1500 • ACR Convergence 2023

    Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies

    Saira Sheikh1, Kevin Withrop2, Jinoos Yazdany3, Sandra Navarra4, Tatsuya Atsuma5, Paula Curtis6, Jose Miyar Olaiz7, Christine Henning8, Roger A. Levy9, William Stohl10 and Daniel Wallace11, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 5Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 6GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, 7GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, 8GlaxoSmithKline, US Medical Affairs, Durham, NC, 9GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 10University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, 11Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
  • Abstract Number: 1851 • ACR Convergence 2023

    Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

    Chiara Gasteiger1, Maria Lobo2, Lun Shen Wong1, Rachel Murdoch1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand

    Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is…
  • Abstract Number: 2169 • ACR Convergence 2023

    Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

    Joanna Kedra1, Benjamin Granger2, Lina El Houari3, Florence Tubach4 and Bruno Fautrel5, 1Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, 2Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, 3Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, 4Centre de pharmaco-épidémiologie de l'APHP, Paris, France, 5Sorbonne Université APHP, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 2247 • ACR Convergence 2023

    Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis

    Leticia Leon1, Dalifer Freites2, Maria Rodriguez Laguna3, Cristina Martinez4, Esther Toledano4, Inmaculada Morado3, Benjamin Fernandez3 and lydia Abasolo2, 1Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Hospital Clinico San Carlos, Madrid, Spain, 4Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain

    Background/Purpose: The impact of gender on biological and targeted synthetic therapies (ts/bDMARDs) used in PsA patients has been scarce studied. Our main objective was to…
  • Abstract Number: 2487 • ACR Convergence 2023

    Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity

    Nan Shen1, Stanislav Ignatenko2, Alexander Gordienko3, Josefina Cortés Hernández4, Nancy Agmon-Levin5, Pongthorn Narongroeknawin6, Katarzyna Romanowska -Prochnicka7, Hana Ciferska8, Masanari Kodera9, James Cheng-Chung Wei10, Piotr Leszczynski11, Joung-Liang Lan12, Eduardo Mysler13, Rafal Wojciechowski14, Tunde Tarr15, Elena Vishneva16, Yi-Hsing Chen17, Yuko Kaneko18, Stephanie Finzel19, Alberta Hoi20, Ajchara Koolvisoot21, Shin-Seok Lee22, Lie Dai23, Hiroshi Kaneko24, Bernadette Rojkovich25, Lingyun Sun26, Eugeny Zotkin27, Jean-Francois Viallard28, Masao Katayama29, Berta Paula Magallares-Lopez30, Tirtha Sengupta31, Carol Sips32 and Stephen J Oliver32, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Charité Research Organisation GmbH, Berlin, Germany, 3SM Kirov Military Medical Academy, St. Petersburg, Russia, 4Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, 5Yabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, 6Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, 7Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 8Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 9Department of Dermatology, Japan Community Healthcare Organization Chukyo Hospital, Nagoya, Japan, 10Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, 11Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznań, Poland, 12China Medical University Hospital, Taichung, Taiwan, 13Organizacion Medica de Investigacion, Buenos Aires, Argentina, 14Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, Poland, 15Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 16LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, 17Taichung Veterans General Hospital, Taichung, Taiwan, 18Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 19Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, 20Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, 21Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 22Chonnam National University Medical School & Hospital, Gwangju, South Korea, 23Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, 24Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan, 25Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary, 26Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 27VA Nasonova Research Institute of Rheumatology, Moscow, Russia, 28CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, 29National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, 30Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 31Novartis Pharma India, Hyderabad, Hyderabad, India, 32Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Ianalumab is a novel defucosylated human IgG1 mAb targeting the receptor for B cell Activating Factor belonging to the TNF Family (BAFF-R) providing potent…
  • Abstract Number: 0355 • ACR Convergence 2023

    Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis

    Ana Isabel Rebollo Gimenez1, Luca Carlini2, Paivi Miettunen3, Ekaterina Alexeeva4, Charlotte Myrup5, Rebecca Nicolai6, Maria Trachana7, Valda Stenevicha8, Constantin Ailioaie9, Elena Tsitsami10, Alexis-Virgil Cochino11, Chiara Pallotti12, Silvia Scala12, Angela Pistorio13, Sebastiaan Vastert14, Joost Swart15 and Nicolino Ruperto16, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, 3University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, 4Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 5Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 7First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, 8Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, 9Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 10Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, 11First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, 12Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 13Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 14University Medical Center Utrecht, Utrecht, Netherlands, 15Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, 16IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy

    Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
  • Abstract Number: 0450 • ACR Convergence 2023

    Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

    Martinus Van de Laar1, Martijn Oude Voshaar1, Peter ten Klooster1, Danyta Tedjo2 and celine van de laar3, 1University of Twente, Hengelo (OV), Netherlands, 2TiH @ University of Twente, Hengelo (OV), Netherlands, 3Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands

    Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
  • Abstract Number: 0588 • ACR Convergence 2023

    Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

    Augustine Jose1, Aishwarya Gopal1, Mamatha Gorijavolu1, Anna C Das2, Jagan Babu K L1, Amrita Nayak1, Chengappa Kavadichanda1 and Molly Mary Thabah1, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 2St.Johns National Academy of Health Sciences, Bengaluru, India

    Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…
  • Abstract Number: 0896 • ACR Convergence 2023

    Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus

    Atsushi Manno1, Tomohiro Honda1, Chiharu Kuwata2, Shiho Ito2, Michinori Kadokura1, Reiko Mizutani3, Shinnosuke Yamada1 and Yoshiaki Tomimori1, 1Daiichi Sankyo Co., Ltd., Shinagawa-ku, Japan, 2Daiichi Sankyo Co., Ltd., Edogawa-ku, Japan, 3Daiichi Sankyo RD Novare Co., Ltd., Edogawa-ku, Japan

    Background/Purpose: The centrality of Toll-like receptor 7 (TLR7) to the pathogenesis of systemic lupus erythematosus (SLE) was recently underscored by a report that high TLR7…
  • Abstract Number: 1134 • ACR Convergence 2023

    Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis

    Jeffrey Shen1, Jayanth Doss1, Ravichandra Karra Gurunath1, Kelly Arps1, Megan Milne2, Rishi Rampersad1, Kees Frelinger1, Michael Hershfield1 and Teresa Tarrant1, 1Duke University, Durham, NC, 2Costal Carolina Health Care, New Bern, NC

    Background/Purpose: Sarcoidosis is a heterogenous granulomatous inflammatory disease that is especially dangerous when it affects the heart where it may cause fatal arrythmias and heart…
  • Abstract Number: 1349 • ACR Convergence 2023

    Paternal Effects of Anti-TNFs in Inflammatory Arthritis

    Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
  • Abstract Number: 1502 • ACR Convergence 2023

    Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study

    Kanako Kojima1, Kunihiro Ichinose1, Toshimasa Shimizu1, Masataka Umeda1, Takahisa Suzuki2, Yoshikazu Nakashima3, Akitomo Okada4, Yoshiro Horai5, Keita Fujikawa6, Toshiyuki Aramaki7, Taiichiro Miyashita8, Masako Furuyama3, Naoki Matsuoka9 and Atsushi Kawakami10, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 3Nagasaki Kita Hospital, Nagasaki, Japan, 4National Hospital Organization Nagasaki Medical Center, Omura, Japan, 5Sasebo City General Hospital, Sasebo, Japan, 6Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, 7Sasebo Chuo Hospital, Sasebo, Japan, 8Miyashita Rheumatology Clinic, Omura, Japan, 9Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, 10Nagasaki University, Nagasaki, Japan

    Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…
  • Abstract Number: 1929 • ACR Convergence 2023

    Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience

    Zeynep Toker Dincer1, Sejla Karup2, Erkin Yilmaz1, Osman Corbali1 and Serdal Ugurlu1, 1Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 54
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology